Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

WT data of set A398E/V and set M1425V/I pooled for better comparison. by Yousra El Ghaleb (22075892)

Subjects:

D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

Subjects:

D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

Subjects:

Astrocytes increase contact with vessels and expression of AQP4 following Mtb infection, which is decreased in cytosis⁺ animals. by Amanda S. Latham (12093638)

“…Decreased expression of AQP4, and endfoot contact, is found in cytosis⁺ animals in the frontal cortex (D and E), cerebral nuclei (J and K), brain stem (P and Q), thalamus (V and W) and hippocampus (BB and CC). …”

TBEV infection decrease levels of 18S and 28S rRNA but not 5S rRNA. by Martin Selinger (3195987)

MVEC microvessel formation is restricted in hydrogels exhibiting increased stiffness or decreased concentration of adhesive peptides. by Rebecca A. Scott (488956)

“…An unpaired student’s t-test detect statistical significance, *p<0.05 for 7.5 wt% hydrogels containing 3 mM RGD relative to either (<b>A, C-F</b>) 15wt% hydrogels containing 3 mM RGD or (<b>G, I-L</b>) 7.5wt% hydrogels containing 1 mM RGD.…”

PFKFB3-4+5 knockdown leads to decreased cell growth and colony formation. by Ulli Heydasch (11091062)

MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

“…<p><b>A.</b> Experimental schedule. All mice underwent behavioral tests following CRS treatment. …”